Clinical trials: Tace
Hepatocellular Carcinoma
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma
The role of transarterial chemoembolization (TACE) as the standard therapy for intermediate-stage hepatocellular carcinoma (HCC) is being challenged by increasing studies which showed that liver resection (LR) is a safe and…
- Trial name
- NCT02755311
- Testing
- liver resection, transarterial chemoembolization, carboplatin
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Hepatocellular Carcinoma
The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is a major tumor type worldwide, especially in China as the sequence of hepatitis B and liver cirrhosis. Activation of the coagulation system occurs commonly in patients with malignancy.
- Trial name
- NCT00827554
- Testing
- LMWH, TACE
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma (HCC)
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
This is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1/L1 monoclonal antibody and either TACE or HAIC…
- Trial name
- NCT07724951
- Testing
- Donafeinib, Transcatheter arterial chemoembolization, PD-1 / PD-L1 monoclonal antibody
- Where
- 8 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Study introduction: this is a multicenter, randomized controlled study of patients with histopathologically confirmed hepatocellular carcinoma (HCC) who have not previously received systematic treatment for HCC, all the patients…
- Trial name
- NCT05056337
- Testing
- Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Donafenib
A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC
This study is expected to recruit 30 patients with unresectable HCC who will be treated with Donafenib combined with PD-1 + TACE.
- Trial name
- NCT05262959
- Testing
- Donafenib, PD-1, TACE
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Advanced Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) followed by Sorafenib with TACE alone in patients with advanced hepatocellular carcinoma.
- Trial name
- TACE (NCT02150317)
- Testing
- TACE+Sorafenib, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma, Surgery
TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Partial hepatectomy is still considered as the conventional therapy for HCC.
- Conditions
- Hepatocellular Carcinoma, Surgery, Ablation
- Trial name
- TACE-RFA (NCT01833286)
- Testing
- TACE+RFA, re-resection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatocarcinoma
Icariin Soft Capsules Combined With TACE as Adjuvant Therapy for HCC
This is a prospective, single-center, phase II study，to evaluate the efficacy and safety of icariin soft capsules combined with TACE as adjuvant therapy in hepatocellular carcinoma (HCC) patients at high risk of recurrence after…
- Trial name
- NCT06900478
- Testing
- Icariin Soft Capsules+TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hua Li
Advanced Adult Hepatocellular Carcinoma
A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC
This is a randomized, multi-center, open-labeled, phase III study in patients with advanced HCC. A total of 338 patients will be randomized (1:1) into one of the two treatment arms, to receive sorafenib with (Arm…
- Trial name
- NCT01829035
- Testing
- Conventional Transarterial Chemoembolization (cTACE)
- Where
- South Korea
- Volunteers
- 339 people
- Sponsor
- National Cancer Center, Korea
Hepatocellular Carcinoma
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer
The purpose of this study is to evaluate overall survival in patients diagnosed with hepatocellular cancer (HCC) treated with HepaSphere/QuadraSphere Microspheres loaded with chemotherapeutic agent doxorubicin compared to…
- Trial name
- HiQuality (NCT01387932)
- Testing
- HepaSphere/QuadraSphere Microspheres, PVA, lipiodol, doxorubicin
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 235 people
- Sponsor
- Merit Medical Systems, Inc.
Liver Neoplasm
Value of Functional Magnetic Resonance Imaging of Hepatocellular Carcinoma After Transarterial Chemoembolization or Transarterial Radioembolization
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide and is commonly treated with transarterial locoregional therapies (transarterial chemoembolization (TACE) or transarterial radioembolization (TARE)).
- Trial name
- NCT04702230
- Testing
- MRI
- Where
- Switzerland
- Volunteers
- 32 people
- Sponsor
- University of Zurich
Unresectable Hepatocellular Carcinoma (HCC)
Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
The goal of this interventional study is to compare treatment response between transarterial chemoembolization (TACE) combined with lenvatinib and lenvatinib monotherapy in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT07408804
- Testing
- TACE (transarterial chemoembolization) combined with targeted therapy (Lenvatinib), Lenvatinib
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- Bangladesh Medical University
Hepatocellular Carcinoma, HCC
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
This is a phase 2 single-arm, open-label clinical trial determining efficacy of cabozantinib in combination with ipilimumab/nivolumab and transarterial chemoembolization (TACE) in subjects with hepatocellular carcinoma (HCC).
- Trial name
- NCT04472767
- Testing
- Nivolumab, Ipilimumab, Cabozantinib
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization
The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACE
The purpose of this randomized, double-blind trial was to compare the effects of preemptive Oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (TACE) of…
- Conditions
- Hepatocellular Carcinoma, Transcatheter Arterial Chemoembolization, Pain, Inflammation
- Trial name
- NCT06041425
- Testing
- Oxycodone, Sufentanil
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Carcinoma, Hepatocellular
A Retrospective Study on the Treatment of Intermediate and Advanced Liver Cancer.
To evaluate the effectiveness of TACE combined with immunotherapy and targeted therapy versus TACE alone in patients with intermediate and advanced liver cancer.
- Trial name
- NCT06205732
- Testing
- Immunotherapy, targeted therapy.
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qianfoshan Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma, Hepatocellular, Cirrhosis
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
This clinical trial is aimed at extending the chance of liver transplantation, through downstaging procedures, to patients with hepatocellular carcinoma (HCC) exceeding conventional Milan Criteria.
- Trial name
- NCT01387503
- Testing
- Liver transplantation
- Where
- 10 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Hepatocellular Carcinoma
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization.
- Trial name
- NCT06478719
- Testing
- FB-1603
- Where
- 2 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Febico Biomedical Corp.
Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
This randomized phase II trial studies how well transarterial chemoembolization (TACE) works compared with TACE plus radiation therapy in treating patients with end stage liver disease, liver tumors, or potential liver transplant…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Recurrent Adult Primary Liver Cancer, Stage I Adult Primary Liver Cancer, Stage II Adult Primary Liver Cancer
- Trial name
- NCT02070419
- Testing
- transarterial chemoembolization, stereotactic radiosurgery
- Sponsor
- Case Comprehensive Cancer Center